HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsPricing
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#189 / 189 Total
IOBT - IO Biotech Inc - Stock Price Chart
TickerIOBT [NASD]
CompanyIO Biotech Inc
CountryDenmark
IndustryBiotechnology
Market Cap96.84MEPS (ttm)-1.49
P/E-EPS this Y5.24%
Forward P/E-EPS next Y20.96%
PEG-EPS past 5Y-27.25%
P/S-EPS next 5Y21.11%
P/B3.67EPS Q/Q-15.24%
Dividend-Sales Q/Q-
Insider Own26.49%Inst Own21.55%
Insider Trans0.09%Inst Trans-6.15%
Short Float0.25%EarningsMay 14/b
Analyst Recom1.00Target Price9.50
Avg Volume151.30K52W Range0.66 - 1.73
May-28-25 09:55AM IO Biotech, Inc. (IOBT) Just Flashed Golden Cross Signal: Do You Buy? (Zacks)
May-20-25 08:05AM IO Biotech Announces Participation in Cowen 6th Annual Oncology Innovation Summit and Jefferies Global Healthcare Conference (GlobeNewswire)
May-15-25 12:11PM IO Biotech price target raised to $14 from $12 at H.C. Wainwright (TipRanks)
May-14-25 08:05AM IO Biotech Reports First Quarter 2025 Financial Results and Business Highlights (GlobeNewswire)
Apr-26-25 03:05PM IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025 (GlobeNewswire)
Apr-25-25 01:00PM IO Biotech Presents New Data at AACR 2025 Supporting Dual Mechanism and Immune Activation of Cancer Vaccines IO102-IO103 and IO170 (GlobeNewswire)
Mar-25-25 04:35PM IO Biotech Announces Acceptance of Abstracts to be Presented at the 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +17.00%
Mar-18-25 08:00AM IO Biotech Named Among Fast Company's World's Most Innovative Companies of 2025 (GlobeNewswire)
Mar-04-25 04:17PM IO Biotech Reports 2024 Business Highlights (GlobeNewswire) +5.91%
Feb-23-25 12:07PM IO Biotech Announces New Preclinical Data for Additional Pipeline Candidate Presented at the AACR-IO Conference (GlobeNewswire)
IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hunter HeidiDirectorMay 30 '25Buy1.3915,00020,88415,000Jun 02 07:53 AM
Ahmad Qasim IftikharChief Medical OfficerDec 23 '24Buy0.8531,35026,55331,350Dec 26 08:50 AM
Zocca Mai-BrittChief Executive OfficerDec 23 '24Buy0.8112,50010,12049,891Dec 23 06:56 PM
Sullivan AmyChief Financial OfficerDec 23 '24Buy0.8310,2508,48384,632Dec 23 06:53 PM
Smith Devin WhittemoreGeneral CounselDec 23 '24Buy0.8112,0009,72016,938Dec 23 06:52 PM
1⋯10⋯141516171819
Affiliate • Advertise • Theme Settings • Contact • Help • Privacy • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2025 FINVIZ.com. All Rights Reserved.